AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05358535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)
Description: The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab.
Study NCT05358535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)
Description: The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab.
Study NCT06209086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: skeletal anchored twin block
Description: This appliance was constructed as the modified Twin Block used for the first group in addition to the following modifications:~* Addition of mini-implants interdentally between the mandibular second premolar and mandibular first molar.~* Wire hooks: wire hook element in the lower part of the appliance was incorporated in the region of incisal capping with free end projecting at the canine region on both sides.~* Intra-oral elastics were attached from the mini-implant to the wire hook bilaterally.
Study NCT04213274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 80 mg RPH-104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
Study NCT04213274 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 80 mg RPH-104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
Study NCT04213274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial
Study NCT04213274 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial
Study NCT04213274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4 mL-glass vial
Study NCT04593329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIRADENTES ASSOCIATION
Description: Tiradentes association tablet
Study NCT04593329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DIPYRONE
Description: Dipyrone 500 mg
Study NCT04593329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRAMADOL
Description: Tramadol 50 mg
Study NCT04593329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TIRADENTES ASSOCIATION PLACEBO
Description: Tiradentes association placebo tablet
Study NCT04593329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DIPYRONE PLACEBO
Description: Dipyrone placebo tablet
Study NCT04593329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIPYRONE PLACEBO
Description: Dipyrone placebo tablet
Study NCT04593329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TRAMADOL PLACEBO
Description: Tramadol placebo capsule
Study NCT04593329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRAMADOL PLACEBO
Description: Tramadol placebo capsule
Study NCT05721625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The aerobic exercise program will be applied at moderate intensity 3 days a week for 8 weeks. Walking will be recommended as an aerobic exercise
Study NCT04800718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Arm
Description: Intervention includes door-to-door screening and awareness generation in 8-12 villages surrounding the Vision Centres
Study NCT06404463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
Description: QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).
Study NCT06404463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Albumin-bound paclitaxel improves the solubility and delivery of paclitaxel to tumor cells by binding to human albumin, facilitating its transportation through the bloodstream and enhancing its uptake into tumor tissue. It works by binding to and stabilizing microtubules within cancer cells, thereby disrupting the normal process of cell division and leading to cell cycle arrest and apoptosis, ultimately resulting in the death of cancer cells.
Study NCT06404463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin, a widely used chemotherapy drug, belongs to the anthracycline class and is effective against various cancers, including breast cancer, leukemia, and sarcomas. It works by intercalating with DNA and inhibiting topoisomerase II, leading to DNA damage and disruption of DNA replication and transcription processes within cancer cells. Despite its efficacy, doxorubicin may cause side effects such as cardiotoxicity and bone marrow suppression, limiting its long-term use in some patients.
Study NCT06404463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a chemotherapy medication commonly used to treat various types of cancers, including lymphoma, leukemia, and breast cancer. It belongs to the class of alkylating agents and works by crosslinking DNA strands, which prevents cell division and leads to cell death. While effective in treating cancer, cyclophosphamide can also cause side effects such as nausea, vomiting, and suppression of the immune system.
Study NCT05598827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tik Tok
Description: The enrolled patients were encouraged to watch Tik Tok without limit starting 24 days before chemotherapy and continuing until the seventh day after chemotherapy.
Study NCT05323565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: adjuvants to 0.25 bupivacaine in TAB block.
Study NCT05323565 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexmedetomidine
Description: adjuvants to 0.25 bupivacaine in TAB block.
Study NCT05637658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: aerobic exercise
Study NCT05721625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue massage
Description: Connective tissue massage will be applied by the physiotherapist 3 days a week for 8 weeks. While the patients are in the sitting position, this massage will be applied on whole back.
Study NCT05978895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted canteen menus
Description: The nutritional intervention consisted in the development of targeted menus aiming at the needs of individuals with ASD and in assessing their acceptance of the targeted menus.~The revision of the standard menus was carried 1) balancing energy and macronutrient content, according to LARN 2014; 2) promoting adequate weekly food frequencies consumption and portions, to provide an adequate and sustainable menus according to CREA 2018; 3) adapting the sensory characteristics of the foods offered to the sensory needs of individuals with ASD.~The acceptance of the targeted menus by the enrolled population was evaluated through meal evaluation forms. These results were compared with the ones collected during the first observational phase (WP1). In fact, referring to the results of WP1, new canteen menus were drafted according to the nutritional and sensory needs of the population.
Study NCT06404463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin, a chemotherapy medication, is part of the anthracycline class and is used in the treatment of various cancers, including breast cancer, ovarian cancer, and soft tissue sarcoma. It functions by interfering with DNA replication and RNA synthesis within cancer cells, ultimately leading to cell death. Despite its efficacy, epirubicin can cause side effects such as nausea, hair loss, and bone marrow suppression.
Study NCT05644184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
Description: Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.
Study NCT05908318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: olfactory training
Description: In this group, patients were performed 24-48h before surgery used phenylethyl alcohol (rose), phytol (press tree), citronella (lemon), eugenol (clove) 4 kinds of smell，twice a day for three days.
Study NCT05644184 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)
Description: Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.
Study NCT05644184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)
Description: The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.
Study NCT05973396 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Fatiguing Task only
Description: Control group: 20-25 minutes \[Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort\] without mentally fatiguing task during low intensity effort pace
Study NCT05973396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical and Mental Fatiguing Task
Description: Experimental group: 20-25 minutes \[Rogue Echo Bike 20 intervals of 10 second of maximal-submaximal effort to 50 seconds of recovery low intensity effort\] with mentally fatiguing task during low intensity effort pace (which includes: stroop test)
Study NCT05436366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soleus loading response in able-bodied participants
Description: Able-bodied participants are enrolled. The robotic ankle device applies ankle joint rotations using a computer-controlled closed-loop algorithm to evoke the soleus loading response during the mid-late stance phase during treadmill walking at a self-selected comfortable fast speed. The algorithm applies ankle perturbations, which are shifts from the natural ankle kinematics to target the soleus loading response in mid-late stance phase every other 4-6 gait cycles. The perturbation magnitude, speed, and timing are controlled by the device to adjust the participant's soleus response. Four-to-five walking bouts are conducted interleaving perturbed and unperturbed walking steps (until collecting data of about 30 perturbed and unperturbed steps per walking bout) leaving at least one unperturbed step before a perturbed step. Changes in the soleus EMG will be compared between perturbed and unperturbed walking steps.
Study NCT05436366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soleus loading response in participants with hemiparesis
Description: Participants with spastic hemiparesis due to a stroke are enrolled. The robotic ankle device applies ankle joint rotations using a computer-controlled closed-loop algorithm to evoke the soleus loading response during the mid-late stance phase during treadmill walking at a self-selected comfortable fast speed. The algorithm applies ankle perturbations, which are shifts from the natural ankle kinematics to target the soleus loading response in mid-late stance phase every other 4-6 gait cycles. The perturbation magnitude, speed, and timing are controlled by the device to adjust the participant's soleus response. Four-to-five walking bouts are conducted interleaving perturbed and unperturbed walking steps (until collecting data of about 30 perturbed and unperturbed steps per walking bout) leaving at least one unperturbed step before a perturbed step. Changes in the soleus EMG will be compared between perturbed and unperturbed walking steps.
Study NCT04748588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 mAb
Description: Casirivimab/imdesimab 1200mg/1200mg OR sotrovimab 500mg OR bamlanivimab 700mg IV x1.~Casirivimab/imdesimab (REGN) and sotrovimab will be the default agents used (according to local availability) unless both unavailable AND virus strain known to be native or alpha (B.1.1.7) in which case bamlanivimab can be used.
Study NCT05644184 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)
Description: The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.
Study NCT06301386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Study NCT06301386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: 200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
Study NCT04699396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilisation With Movement 1
Description: Application of a sustained passive accessory movement to a joint (talus or fibula) while the patient actively performs a forward lean/lunge that was previously limited.~3 sets of 10 repetitions of a glide applied to the talus were performed, followed by 3 sets of 10 repetitions of a glide applied to the fibula.
Study NCT04699396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilisation With Movement 2
Description: Application of a sustained passive accessory movement to a joint (talus or fibula) while the patient actively performs a forward lean/lunge that was previously limited.~3 sets of 10 repetitions of a glide applied to the fibula were performed, followed by 3 sets of 10 repetitions of a glide applied to the talus.
Study NCT04699396 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo group participants performed the same number of sets and repetitions (6 sets of 20 repetitions) of lean/lunge forward into dorsiflexion, without any glide application.
Study NCT04697173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single consent
Description: A single consent form for possible procedures the child may undergo while in the PICU
Study NCT04754074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Weekly education related to behavior change
Study NCT04754074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized coaching
Description: Weekly calls with personalized coaches in behavior modification, nutrition, and physical activity/exercise.
Study NCT04754074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly behavior modification challenges
Description: Weekly challenges to address behavior change
Study NCT05663593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31858, tablet
Description: Starting dose in single ascending dose: 5 mg
Study NCT05663593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, tablet
Description: Matching placebo
Study NCT05250804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helfer Skin Tap Technique
Description: Helfer Skin Tap Technique is a technique in which the researcher taps the Dorso gluteal muscle by counting 1-15 with the palmar aspect of fingers (non-dominant hand) in rhythmic manner before inserting the injection intra muscularly at 90 degree and remove the needle quickly again by tapping and counting 1-3.
Study NCT06490965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation (TMS) involves generating a magnetic field with specific spatial and temporal properties, allowing the induction of electric current in conductive material near this field. The electro-physiological principle of TMS is based on placing a coil over the skull that will induce a magnetic field generating action potentials in neuronal tissue in response to each TMS pulse. The repetitive application of TMS pulses (rTMS) allows for the modulation of neuronal excitability for a period after rTMS, ranging from inhibition, in the case of low frequencies (\~1 Hz), or facilitation if high frequencies (equal to or greater than 5 Hz) are used.
Study NCT06490965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Transcranial Magnetic Stimulation (TMS) involves generating a magnetic field with specific spatial and temporal properties, allowing the induction of electric current in conductive material near this field. The electro-physiological principle of TMS is based on placing a coil over the skull that will induce a magnetic field generating action potentials in neuronal tissue in response to each TMS pulse. The repetitive application of TMS pulses (rTMS) allows for the modulation of neuronal excitability for a period after rTMS, ranging from inhibition, in the case of low frequencies (\~1 Hz), or facilitation if high frequencies (equal to or greater than 5 Hz) are used.
Study NCT06490965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuronavigation
Description: Neuronavigation is a non-invasive method that allows the creation of computerized three-dimensional models of brain structures based on neuroimaging exams of each individual (e.g., cranial magnetic resonance imaging). As such, this method has been used for various purposes, such as assisting in neurosurgery or mapping functional regions of the brain, but also in the context of TMS (Transcranial Magnetic Stimulation). In this latter area, its use as support for TMS has been employed for therapeutic, diagnostic, and research purposes. The neuronavigation system consists of several components, namely a locating camera, locators for the TMS coil, an adjustable headband with locators, a calibration system for these elements, and the neuronavigation software, which is installed on a supporting computer.
Study NCT05210764 — intervention group
Intervention type: DRUG
Intervention: propofol
Description: General anesthesia is induced and maintained mainly with propofol.
Study NCT05210764 — intervention group
Intervention type: DRUG
Intervention: sevoflurane
Description: General anesthesia is induced and maintained mainly with sevoflurane.
Study NCT05210764 — intervention group
Intervention type: DRUG
Intervention: S-ketamine
Description: General anesthesia is induced mainly with S-ketamine and maintained mainly with propofol.
Study NCT06142526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DividPro film
Description: DividPro Film is a sterile biodegradable translucent film that served as a physical barrier for preventing the adhesion between two adjacent layers of tissue in wound healing process.
Study NCT04856670 — intervention group
Intervention type: PROCEDURE
Intervention: Cataract surgery
Description: Cataract surgery- Manual or femtosecond laser assisted
Study NCT03610542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triggers for anxiety
Description: Students learn about different triggers for anxiety, what the signs and indicators of anxiety are, and identify their own triggers for anxiety
Study NCT05993871 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Evaluation/Questionnaires
Description: Anthropometric measures, somatosensory assessment (NPS, UENS, TCNS), autonomic assessment (COMPASS-31, Ewing battery), and severity and quality of life evaluation (NPS, TCNS, COMPASS-31, and EuroQOL-5D-5L index score)
Study NCT06490965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuronavigation
Description: Neuronavigation is a non-invasive method that allows the creation of computerized three-dimensional models of brain structures based on neuroimaging exams of each individual (e.g., cranial magnetic resonance imaging). As such, this method has been used for various purposes, such as assisting in neurosurgery or mapping functional regions of the brain, but also in the context of TMS (Transcranial Magnetic Stimulation). In this latter area, its use as support for TMS has been employed for therapeutic, diagnostic, and research purposes. The neuronavigation system consists of several components, namely a locating camera, locators for the TMS coil, an adjustable headband with locators, a calibration system for these elements, and the neuronavigation software, which is installed on a supporting computer.